Expression and Regulation of the Lipoprotein Lipase Gene in Human Adrenal Cortex*
(Received for publication, December 1, 1996, and in revised form, April 22, 1996)
Bart Staelst, Geneviève Martin, Monica Martinez§, Caroline Albert1, Julia Peinado-Onsurbell, Régis Saladin, Dean W. Hum1, Manuel Reina§, Senen Vilaros, and Johan Auwerx **
From U.325 INSERM, Département d’Athérosclérose, Institut Pasteur, 1 Rue Calmette, 59019 Lille, France, the §Department of Cell Biology, University of Barcelona, Avda. Diagonal 645, Barcelona (08028), Spain, the | Department of Biochemistry and Molecular Biology, University of Barcelona, Spain, and the \Laboratoire d’Endocrinologie Moléculaire, Le Centre Hospitalier de l’Université Laval, 2705 Blvd. Laurier, Québec, G1V 4G2 Canada
Lipoprotein lipase (LPL), an enzyme which hydro- lyzes triglycerides and participates in the catabolismof remnant lipoproteins, plays a crucial role in energy and lipid metabolism. The goal of this study was to analyze the expression and regulation of the LPL gene in human adrenals. Reverse transcriptase-polymerase chain reac- tion amplification and sequence analysis demonstrated the presence of LPL mRNA in fetal and adult human adrenal cortex. Furthermore, the human adrenocortical carcinoma cell line, NCI-H295, expresses LPL mRNA and protein, which is localized to the outer cellular mem- brane as demonstrated by immunofluorescence confo- cal microscopy and can be released in the medium by heparin addition. To asses whether the LPL gene is reg- ulated by agents regulating adrenal steroidogenesis, NCI-H295 cells were treated with activators of second messenger systems. Whereas the calcium-ionophore A23187 did not affect LPL gene expression, treatment with phorbol 12-myristate 13-acetate decreased LPL mRNA levels in a time- and dose-dependent manner. This decrease after phorbol 12-myristate 13-acetate was associated with diminished heparin-releasable LPL mass and activity in the culture medium. Addition of the cAMP analog 8-Br-cAMP to NCI-H295 cells resulted in a rapid, but transient dose-dependent induction of LPL mRNA. Treatment with the protein synthesis inhibitor cycloheximide gradually induced, whereas simultane- ous addition of cAMP and cycloheximide superinduced LPL mRNA levels. Nuclear run-on analysis indicated that the effects of cAMP and cycloheximide occurred at the transcriptional and post-transcriptional level, re- spectively. Transient co-transfection assays demon- strated that the first 230 base pairs of the proximal LPL promoter contain a cAMP-responsive element activated by protein kinase A and transcription factors belonging to the CREB/CREM family. These data indicate that LPL is expressed in human adrenal cortex and regulated in
NCI-H295 adrenocortical carcinoma cells by activators of the protein kinase A and protein kinase C second messenger pathways in a manner comparable to P450scc, which catalyzes the first step in adrenal steroi- dogenesis. These observations suggest a role for LPL in adrenal energy and/or lipid metabolism and possibly in steroidogenesis.
The adrenal cortex is the major site of the biosynthesis of steroid hormones, such as glucocorticoids and mineralocorti- coids (for review, see Ref. 1). Adrenal steroidogenesis is con- trolled by the action of specific peptide hormones (2). In the adrenal cortex, glucocorticoid synthesis is stimulated by the anterior pituitary-derived adrenocorticotropic hormone (ACTH),1 which, after binding to a specific cell surface receptor, activates adenylate cyclase, resulting in elevated intracellular cAMP concentrations and activation of the protein kinase A (PKA) signal transduction pathway (2). Mineralocorticoid syn- thesis, on the other hand, is induced by angiotensin-II, which activates the protein kinase C (PKC) pathway of intracellular second messengers. The first step in the enzymatic conversion of cholesterol into steroid hormones is catalyzed by the mito- chondrial cytochrome P450 side chain cleavage enzyme (P450scc), which catalyzes the conversion of cholesterol into pregnenolone. Long term regulation of steroidogenesis by these peptide hormones occurs via changes in P450scc gene expres- sion and transcription (3-5). Human adrenals derive the cho- lesterol necessary for steroid hormone synthesis mainly by receptor-mediated endocytosis of low density lipoproteins (LDL) and, to a lesser extent, by de novo synthesis, the rate- limiting step of which is catalyzed by the enzyme 3-hydroxy 3-methylglutaryl-coenzyme A reductase (6-8). Although pa- tients homozygous for familial hypercholesterolemia have a mild impairment in cortisol secretion during maximal ACTH stimulation (9), the absence of adrenal dysfunction in patients with defects in the LDL-receptor pathway treated with hydroxy 3-methylglutaryl-coA reductase inhibitors, such as mevinolin, suggested the existence of alternative pathways of cholesterol delivery to the adrenal for steroid synthesis (10).
Lipoprotein lipase (LPL) occupies a pivotal position in both
* This word was supported in part by grants from INSERM, CNRS, Fondation pour le Recherche Médicale, the Comision Interministerial de Ciencia y Tecnologia (Grant SAF-92-0897; PB94-1548), the Fondo de Investigaciones Sanitarias from Ministerio de Sanidad (Grant 93/ 0423E), and the European Community (BIOMED PL-921243). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “adver- tisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
# Chargé de Recherche of the Centre National de la Recherche Sci- entifique (CNRS). To whom correspondence should be addressed: U.325 INSERM, Département d’Athérosclérose, Institut Pasteur, 1 Rue Calmette, 59019 Lille, France. Fax: 33-20-87-73-60; Tel .: 33-20-87-73- 88.
** Directeur de Recherche of the Centre National de la Recherche Scientifique (CNRS).
1 The abbreviations used are: ACTH, adrenocroticotropic hormone; apo, apolipoprotein; CAT, chloramphenicol acetyltransferase; CHX, cy- cloheximide; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; LPL, lipoprotein lipase; PKA, protein kinase A; PKC, protein kinase C; PMA, phorbol 12-myristate 13-acetate; P450scc, cytochrome P450 side chain cleavage enzyme; PIPES, 1,4-piperazinediethanesulfonic acid; VLDL, very low density lipoprotein; PCR, polymerase chain reaction; bp, base pair(s); RT, reverse transcriptase; CREB, cAMP response ele- ment-binding protein(s); CREM, cAMP response element modulator.
lipoprotein and energy metabolism. Located as a homodimer on the capillary endothelium of tissues, LPL hydrolyzes triglycer- ides in chylomicrons and very low density lipoprotein (VLDL) particles using apoC-II as a co-factor (11). The released free fatty acids are taken up by the underlying tissue for oxidation to generate ATP (muscle), for storage (adipose tissue), or for secretion in milk (mammary gland). In addition to its lipolytic activity on triglyceride-rich lipoprotein particles, LPL func- tions as a ligand for the VLDL receptor (12), the LDL receptor- related protein (13), and the LDL receptor (14-16), implicating a role for LPL in the uptake of cholesterol-rich remnant parti- cles (for review, see Ref. 17). The cDNA (18), genomic structure (19, 20), and chromosomal location (chromosome 8 (21)) of the human LPL gene have been determined. LPL is expressed in a number of differentiated tissues, such as adipocytes, macro- phages, lactating mammary gland, and muscle (for review, see Ref. 11). In contrast, in liver LPL is only expressed in fetal and neonatal liver and becomes extinguished 3 weeks after birth (22, 23).
In view of the pivotal role of LPL both in energy and lipopro- tein metabolism, the main objective of the current investigation was to analyze whether LPL is expressed in the human adrenal cortex, a major cholesterol metabolizing tissue. Our results demonstrate the presence of LPL mRNA both in fetal and adult adrenal cortex. Furthermore, LPL is expressed in the recently characterized human adrenocortical carcinoma cell line, NCI- H295 (24, 25), where it is located on the plasma membrane and can be released by heparin treatment. LPL expression in NCI- H295 cells is regulated by cAMP and phorbol esters, activators of the PKA and PKC second messenger pathways, respectively, in a manner reminiscent of the regulation of the rate-limiting enzyme in adrenal steroidogenesis, P450scc. These data there- fore suggest a role for LPL in adrenal energy and lipoprotein metabolism.
EXPERIMENTAL PROCEDURES
Materials-Cycloheximide (CHX), transferrin, selenium, insulin and Hepes were obtained from Boehringer Mannheim (Mannheim, Ger- many) and fatty acid-free bovine serum albumin, dithiothreitol, su- crose, PIPES, glycerol trioleate, 8-Br-cAMP, phorbol 12-myristate 13- acetate (PMA), and the calcium ionophore, A-23187, from Sigma. Superscript reverse transcriptase and cell culture media were from Life Technologies (Gaithersburg, MD). Glycerol tri-[9,10-(n)-3H]oleate was obtained from Amersham International and [Q-32P]dCTP, [a-32P]UTP, and [3H]chloramphenicol from ICN Nucleotides (Costa Mesa, CA).
Cell Culture-Human monocyte THP-1, hepatoblastoma HepG2, choriocarcinoma JEG-3, and adrenocortical carcinoma NCI-H295 cells were obtained from the ATCC. NCI-H295, THP-1, JEG-3, and HepG2 cell cultures were maintained exactly as described previously (24, 26, 27). PMA and A-23187, dissolved in acetone, and 8-Br-cAMP and CHX, dissolved in sterile H20, were added to the medium at the indicated concentrations and for the indicated periods of time. Control cells re- ceived vehicle only. In experiments for LPL protein and activity deter- mination, heparin was added to the culture medium at a concentration of 100 milliunits/ml.
Tissue and Cell RNA Extraction and Analysis-Human total fetal adrenals were dissected free and immediately frozen in liquid nitrogen. Care was taken not to contaminate the samples with adipose tissue. Human adult adrenals were harvested and the tissue layer enriched in fasciculata cells was prepared as described previously (28). Briefly, adipose tissue was carefully removed from the adrenal gland using scissors and thin tissue slices of the fasciculata layer were obtained using a Stadie-Riggs tissue slicer. Total cellular RNA was prepared by the guanidinium isothiocyanate/cesium chloride procedure (tissues) or by the acid guanidinium thiocyanate/phenol-chloroform method (cell cultures) (29, 30). Poly(A+) RNA was subsequently prepared using Poly(A)Quik push columns (Stratagene, La Jolla, CA). For analysis of LPL expression in adult and fetal adrenal and NCI-H295 cells, total RNA (50 ng) was reverse transcribed using random hexamer primers and Superscript reverse transcriptase. LPL mRNA was subsequently PCR amplified (35 cycles of 1 min at 94 ℃, 1 min at 57 ℃, 1 min at 72 °℃) using as primers the sense oligo GCA AGC TTG GTA CCA ATG
GAG AGC AAA GCC CTG (containing HindIII/KpnI cloning sites) and the antisense oligo TAC ATT CCT GTT ACC GTC CAG CCA TGG ATC (containing a NcoI cloning site), yielding a fragment of the expected size of 277 bp (18). This fragment spans exons 1 and 2 of the human LPL gene (19), which excludes potential contamination of the RNA samples with genomic DNA. RNA from HepG2 and differentiated THP-1 cells were simultaneously amplified as negative and positive controls for LPL expression, respectively (26, 27). GAPDH-specific primers (sense primer: TGA TGA CAT CAA GAA GGT GGT GAA G; antisense primer: TCC TTG GAG GCC ATG TGG GCC AT) were used as control for the RT-PCR reaction (expected fragment size: 239 bp) (31). The resulting products were separated on a 2% agarose gel and subsequently sub- cloned into the pUC19 plasmid vector. Sequence analysis revealed complete identity to the previously reported human LPL cDNA sequence (18).
Northern and dot blot hybridizations of total cellular RNA and poly(A+) RNA were performed as described previously (23) using the human LPL cDNA clone, pHLPL-26, as a probe (26). The human P450scc cDNA probe was prepared by RT-PCR amplification based on the published sequence (32). A GAPDH probe was used as a control probe (31). All cDNA probes were labeled by random primed labeling (Boehringer Mannheim). Filters were hybridized to 1.5 × 106 cpm/ml of each probe as described (23). They were washed once in 0.5 x SSC and 0.1% SDS for 10 min at room temperature and twice for 30 min at 65 ℃ and subsequently exposed to x-ray film (X-Omat-AR, Kodak). Autora- diograms were analyzed by quantitative scanning densitometry (Bio- Rad GS670 Densitometer) as described (23).
Isolation of Nuclei and Transcriptional Rate Assay-Nuclei were prepared from NCI-H295 cells treated with 8-Br-cAMP (300 µM), CHX (10 µg/ml), both 8-Br-cAMP and CHX, or vehicle and transcription run-on assays were performed as described by Nevins (33). Equivalent counts of nuclear RNA labeled with [@-32P]UTP (3000 Ci/mmol) were hybridized for 36 h at 42 ℃ to 5 µg of LPL, P450scc, GAPDH, and vector DNA (pBluescript) immobilized on Hybond-C Extra filters (Amersham). After hybridization, filters were washed at room temperature for 10 min in 0.5 x SSC and 0.1% SDS and twice for 30 min at 65 ℃ and subse- quently exposed to x-ray film (X-Omat-AR, Kodak). Quantitative anal- ysis was performed by scanning densitometry (Bio-Rad GS670 densitometer).
Transient Transfection Experiments-Cloning of the human LPL gene promoter and construction of the LPL gene promoter CAT vectors were previously described (19, 34). The different 5’ LPL promoter deletions were subcloned in a luciferase expression vector and were kindly provided by Dr. S. Deeb. The expression vectors pSG5-CREB and pSG5-CREMT were a kind gift from Dr. P. Sassone-Corsi, and the PKA expression vectors were a kind gift from Dr. S. Mc Knight. NCI-H295 and JEG-3 cells were transfected in Dulbecco’s modified Eagle’s mini- mal essential medium by the calcium phosphate co-precipitation proce- dure with a mixture of plasmids, which contained in addition to the reporter (3 µg) and expression vector(s) (1 µg), a cytomegalovirus driven ß-galactosidase vector used as an internal control for transfection effi- ciency. All samples were complemented to an equal total amount of plasmid DNA using empty pSG5 plasmid vector. After 8 h of incubation cells were changed to fresh medium for another 16 h and cells were subsequently treated with 8-Br-cAMP (300 µM) or solvent for a further 6 h. CAT and luciferase activities were determined on cell extracts as described (35, 36).
LPL Mass and Activity Assays-LPL mass was determined by a solid phase sandwich enzyme-linked immunosorbent assay using a chicken polyclonal antibody against LPL for coating and the 5D2 monoclonal antibody for detection as described (37). LPL activity was determined by the method of Ramirez et al. (38) with minor modifications. The assay mixture contained 0.6 mm glycerol tri-[9,10-(n)-3H]oleate (12 Ci/ mol), 50 mM MgCl2, 0.05% fatty acid-free bovine serum albumin, 3% rat serum (preheated for 30 min at 56 ℃), 25 mM PIPES (pH 7.5), and 0.02 ml of sample in a final volume of 0.2 ml. After incubation for 30 min at 25 ℃, the reaction was stopped and [3H]oleate was separated from the substrate and quantified as described previously (39). The amount of enzyme catalyzing the release of 1 umol/min of oleate is defined as 1 unit.
Western Blotting-To obtain NCI-H295 cell extracts, cells were lysed in a buffer containing 1% (w/v) Triton X-100, 5 µg/ml leupeptin, 2 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 0.5 unit/ml aprotinin (Sig- ma) in phosphate-buffered saline. The lysed cells were scraped, rapidly frozen in liquid nitrogen, and sonicated for 30 s at maximum potency. Next, the extract was centrifuged 10 min at 13,000 rpm in an Hereaus Biofuge A centrifuge at 4 ℃. The supernatant (20 pl) was loaded onto a SDS-polyacrylamide gel. After electrophoresis, the gel was blotted to
nitrocellulose (Schleicher and Schuell, Dassel, Germany) at 15 volts for 1 h using the semi-dry system (Bio-Rad). LPL was detected with 10 µg/ml monoclonal antibody against bovine LPL (5D2) (Oncogene, Uniondal, NY) and a secondary peroxidase-conjugated anti-mouse an- tibody at a dilution 1/2000 (Dakopatts, Glostrup, Denmark). The blot was developed with the ECL system from Amersham. As controls, purified bovine LPL (kindly provided by Dr. Gunilla Olivecrona, Uni- versity of Umeå, Sweden) and cell extracts of COS1 cells transfected with the full-length human LPL cDNA were used (40).
Immunofluorescence and Confocal Microscopy-For immunofluores- cence, cells, grown on glass coverslips, were rinsed briefly in phosphate- buffered saline, fixed with methanol (-20 ℃) for 2 min, washed twice in phosphate-buffered saline, incubated with a polyclonal antibody against human LPL, and detected using fluorescein isothiocyanate- conjugated swine anti-rabbit immunoglobulins as described (40). Pre- immune rabbit antibodies were used as negative controls. For confocal microscopy studies a Leica TCS 4D (Leica Lasertechnik GmbH, Heidel- berg, Germany) confocal scanning laser microscope adapted to an in- verted Leitz DMIRBE microscope was used. Relative intensity analysis was made using the Leica TCS software.
Flow Cytometry-For flow cytometry NCI-H295 cells were fixed with ethanol (-20 ℃) for 2 min, washed twice in phosphate-buffered saline, and processed in suspension with the same primary and secondary antibodies used for immunofluorescence. Flow cytometry was done on an Epics Elite flow cytometer (Coulter Electronics Corporation, Hi- aleah, FL). Excitation was done using a standard 488 nm air-cooled argon-ion laser at 15 milliwatts power. The instrument was set up with the standard configuration. Forward scatter, side scatter, green fluo- rescence (525 nm BP filter) from fluorescein isothiocyanate, and time were measured. Optical alignment was based on optimized signal from 10-nm fluorescent beads (Immunocheck, Coulter Corp.).
RESULTS
LPL Is Expressed in Human Fetal Adrenal, Human Adult Adrenal Cortex, and the Adrenocortical Carcinoma Cell Line, NCI-H295-To determine whether the LPL gene is expressed in the human adrenal, RNA was extracted from human fetal total adrenal and analyzed by RT-PCR amplification using LPL-specific primers. RT-PCR amplification yielded a DNA fragment of the expected size of 277 bp (18), indicating the presence of LPL mRNA in human fetal adrenal (Fig. 1, A and B). A fragment of similar size was obtained after RT-PCR amplification of RNA from the human monocyte cell line, THP-1, which expresses the LPL gene when differentiated into macrophages by phorbol ester treatment (26) (Fig. 1A). By contrast, no amplification product was obtained using RNA from the human hepatoma cell line, HepG2, which does not express the LPL gene (27) (Fig. 1A). As a control, GAPDH mRNA could be detected in all cell lines and tissues examined (Fig. 1, A and B).
To determine whether LPL is expressed in the steroid-syn- thesizing part of the adrenal, RNA was prepared from adult adrenal cortex. RT-PCR analysis demonstrated the presence of LPL mRNA in the human adrenal cortex. Similarly to human adrenal cortex, LPL mRNA could be detected by RT-PCR anal- ysis in the recently characterized human adrenocortical carci- noma cell line, NCI-H295, which actively synthesizes the major adrenal steroids (24) (Fig. 1, A and B). Furthermore, Northern blot analysis of NCI-H295 poly(A+) RNA revealed the existence of three distinct LPL mRNA species (Fig. 1C). In contrast to THP-1 cell LPL mRNA (41), however, the largest LPL mRNA species was clearly the most abundant form in NCI-H295 cells. The resulting PCR products from human adrenal and NCI- H295 cells were cloned in pBluescript and sequence analysis revealed complete identity to the previously published human LPL cDNA (not shown) (18), thereby confirming that LPL is present both in human fetal and adult adrenal cortex and in NCI-H295 cells.
To detect whether LPL protein was present in NCI-H295 cells, three different immunochemical approaches were used. By Western blot analysis of total cell extracts using a specific
A
Marker
Mix only
Hep-G2
NCI-H295
Fetal adr
Marker
Mix only
Hep-G2
NCI-H295
Fetal adr
Marker
C
THP-1
THP-1
741
575
521
329
260
225
180
-28S
B
Marker
Mix only
NCI-H295
Adult adr
Fetal adr
Marker
Mix only
NCI-H295
Adult adr
Fetal adr
Marker
713-
-18S
417.
311
249
200
151
LPL
GAPDH
LPL
monoclonal antibody against bovine LPL (5D2) a single band of an apparent molecular mass of 58-60 kDa was detected (Fig. 2A). The electrophoretic mobility of this band was identical to human LPL produced in COS1 cells transfected with the hu- man LPL cDNA and was slightly higher when compared to LPL purified from bovine milk. To identify the cellular distribution of LPL in NCI-H295 cells, immunofluorescence analysis using polyclonal antibodies against human LPL was performed (Fig. 2B). Confocal microscopy analysis of immunofluorescence ex- periments revealed that LPL staining in NCI-H295 cells was intense and preferentially located in the cell periphery (Fig. 2B), suggesting that at least part of the detected LPL is bound to the cell surface. Parallel experiments using paraformalde- hyde-fixed and non-permeabilized cells (not shown), indicated that LPL immunostaining could be detected on the surface of NCI-H295 cells. Flow cytometry analysis of the cell population incubated with the same antibodies used in immunofluores- cence experiments further confirmed the presence of LPL in NCI-H295 cells (Fig. 2C).
To determine whether LPL is secreted by NCI-H295 cells, LPL activity and mass were determined next in the cell culture medium. LPL activity in the medium increased gradually dur- ing a 24-h incubation period (Fig. 3A). This increase was most pronounced when NCI-H295 cells were incubated in the pres- ence of heparin (Fig. 3A), which releases LPL from binding to the cell surface heparin sulfate-proteoglycans and protects it from degradation in the cell culture medium (11). In addition, heparin treatment resulted in the appearance of detectable LPL immunoreactivity in the cell culture medium (Fig. 3B). In the absence of heparin LPL mass was undetectable in the medium, which is most likely due to the lower sensitivity of the mass determination by enzyme-linked immunosorbent assay compared to the LPL activity assay (Fig. 3B).
A
1 2 3
B
LPL
Control
C
LPL
Control
number of cells
0
number of cells
1
A
D
c
B
I-
D
I
10
1000”
0
1
.1
1
16
LPL mRNA Is Regulated by Phorbol Ester, but Not by Cal- cium Ionophore-To examine LPL regulation by activators of the angiotensin-II signal transduction pathway, which modu- lates the expression of steroidogenic enzymes, NCI-H295 cells were treated with the phorbol ester PMA, an activator of the PKC second messenger pathway, and the calcium ionophore, A-23187, which mobilizes intracellular calcium. Similarly to P450scc (24), which catalyzes the first step in adrenal steroi- dogenesis, PMA treatment resulted in a time-dependent de- crease in LPL mRNA levels, which was already apparent after 6 h and reached a nadir after 12 h of treatment (Fig. 4A). Furthermore, this decrease in LPL mRNA after PMA was dose-dependent (Fig. 4B). Under these conditions, GAPDH mRNA levels did not change significantly, thereby confirming our previous observations (24). The decrease in LPL mRNA levels after PMA was followed at 24 and 48 h after PMA by a decreased LPL activity (Fig. 5A) and secretion of LPL protein (Fig. 5B) in the cell culture medium. In contrast to treatment with PMA, addition of the calcium ionophore A-23187 did not change significantly LPL mRNA levels when compared to GAPDH mRNA (data not shown).
Regulation of LPL Gene Expression by cAMP-Next, it was
1500
A
B
LPL activity (uU/106 cells)
-8
LPL mass (ng/106 cells)
O- Heparin
- Heparin
1000
+ Heparin
+ Heparin
-6
-4
500-
₹
-2
O
-0
0
0
3
6
12
24
0
24
Time (hr)
LPL mRNA (% induction)
A
B
LPL mRNA (% induction)
100
100
75
50
50.
-25
036 12
24
48
0 0.1 1 10 100
Time after PMA(hr)
PMA (ng/ml)
examined whether LPL mRNA levels are regulated by cAMP, an activator of the PKA signal transduction pathway which mediates the adrenal response to ACTH. When NCI-H295 cells were incubated with the cAMP analog, 8-Br-cAMP, LPL mRNA levels increased rapidly (within 3 h) by 3-fold, but this induc- tion was transient, already decreasing after 12 h and reaching baseline values within 24 h after addition of 8-Br-cAMP (Fig. 6A). When NCI-H295 cells were treated with the protein syn- thesis inhibitor, CHX, LPL mRNA levels increased more grad- ually reaching a maximum 3-fold induction after 12-24 h (Fig. 6, A and B). Simultaneous treatment of NCI-H295 cells with 8-Br-cAMP and CHX, however, resulted in a tremendous su- perinduction of LPL mRNA levels leading to an approximately
12
LPL activity (mU/106 cells)
A
PO-
B
9
LPL mass (ng/106 cells)
10
O Control
O Control
60
PMA
PMA
8
6
40
4
POLL
20
2
0
6 12
24
48
0 6 12
24
48
Time after PMA(hr)
8-fold increase within 3 h and a 13-fold induction 6-12 h after treatment (Fig. 6, A and B). By contrast, the induction of P450scc mRNA by 8-Br-cAMP was comparable in the presence or absence of CHX (Fig. 6B), thereby confirming previous ob- servations that P450scc induction by cAMP in NCI-H295 cells is independent of de novo protein synthesis (24).
To analyze the dose-dependence of LPL mRNA induction by CAMP, NCI-H295 cells were treated with different doses of 8-Br-cAMP and harvested after 6 h, the optimal time point for cAMP induction of LPL gene expression (Fig. 6A). The induc- tion of LPL mRNA by 8-Br-cAMP was clearly dose-dependent, being maximal at a dose of 1000 µM (Fig. 7). A similar dose-de- pendent effect of 8-Br-cAMP was observed on P450scc mRNA levels (Fig. 7).
cAMP Induces LPL Gene Expression at the Transcriptional Level, Whereas CHX Acts at the Post-transcriptional Level-To study the mechanism of induction of LPL gene expression by cAMP and/or CHX, nuclear run-on experiments were per- formed next. LPL gene transcription rates increased when NCI-H295 cells were treated for 2 h with 8-Br-cAMP (Fig. 8). CHX alone did not affect LPL transcription and simultaneous addition of CHX and 8-Br-cAMP resulted in an induction com- parable to 8-Br-cAMP alone (Fig. 8). Similarly to LPL, P450scc gene transcription increased after 8-Br-cAMP independent whether CHX was present or not (Fig. 8). When NCI-H295 cells were treated for 6 h similar results were obtained: 8-Br-cAMP, but not CHX, induced LPL gene transcription and simultane- ous addition of 8-Br-cAMP and CHX resulted in an induction comparable to 8-Br-cAMP alone (data not shown). These data indicate that cAMP treatment induces LPL expression at the transcriptional level, whereas LPL expression is regulated at a post-transcriptional level by protein synthesis inhibition.
PKA and the Transcription Factors CREB/CREM Activate LPL Gene Promoter Transcription in the Steroidogenic Cell Lines NCI-H295 and JEG-3-In order to test whether 5’-up- stream regulatory sequences in the human LPL gene mediate the inductive effects of cAMP on LPL transcription, transient transfection experiments were performed next. When NCI- H295 cells were transfected with a luciferase expression vector
A
o
a
LPL mRNA (% induction)
1250
1000
750
b
CAMP
500
CHX
CHX + CAMP
250
0123
6
12
24
Time (hr)
B
Control
CAMP
CHX+CAMP
CHX
Control
CAMP
CHX+CAMP
CHX
-LPL
-P450scc
-GAPDH
12
Time (hr)
24
driven by different 5’-deletions of human LPL gene promoter, all constructs were induced to a similar extent by cAMP, indi- cating the presence of a cAMP-response element (CRE) in the most proximal 230 bp (AN-LUC) of the human LPL gene pro- moter (not shown and Fig. 9A). In order to determine the role of transcription factors of the CREB/CREM family (42, 43), which are activated after phosphorylation by PKA (44, 45), the prox- imal -230-bp LPL gene promoter-containing AN-LUC vector was co-transfected with the activator CREMT (46) and/or PKA expression vectors into NCI-H295 cells. Co-transfection of CREM alone activated LPL transcription 2-fold and addition of 8-Br-cAMP (300 µM) resulted in an enhanced 5-fold induction (Fig. 9A). When a wild-type PKA expression vector alone was co-transfected LPL promoter activity was induced approxi- mately 3-fold. Co-transfection of PKA in the presence of CREMT activated the LPL promoter to a similar extent com- pared to CREMT and cAMP (Fig. 9A). Finally, co-transfection experiments were performed in human placental choriocarci- noma JEG-3 cells, another steroidogenic cell line, in which the P450scc gene is expressed and under control of cAMP (47, 48). Although the human placenta expresses the LPL gene (49),
LPL
mRNA (% induction)
750
O- - OP450scc
.. OGAPDH
500
250
0
30
100
300
1000
Dose (u.M)
A
B
Control
CAMP
ZICHX
&CHX+CAMP
% of control
Control
CAMP
CHX+CAMP
CHX
200
LPL
100
P450scc
GAPDH
BSK
LPL
P450scc
JEG-3 cells do not contain endogenous LPL.2 Co-transfection of the -230-bp proximal LPL promoter-containing CAT vector with a wild-type PKA expression vector resulted in a small induction of CAT activity (Fig. 9B). This induction was not observed when a mutated PKA expression vector, which can no longer phosphorylate CREB/CREM, was co-transfected into these cells. Co-transfection with CREB resulted in a strong activation of the LPL promoter, which was further enhanced by wild-type PKA, but not by mutated PKA expression vector. These data indicate that transcription factors belonging to the CREB/CREM family can activate the LPL promoter in steroi- dogenic cells and may participate in the activation of LPL gene transcription by cAMP.
DISCUSSION
The results from this study show that the LPL gene is ex- pressed in human fetal and adult adrenal cortex. Previous reports have indicated the presence of LPL mRNA in rat, guinea pig, and human total adrenal glands (18, 50-53). In rats, however, LPL expression was mainly confined to the adrenal medulla (52), whereas in guinea pig LPL immunore-
Luciferase units (% induction)
A
B
KS+-AN-CAT
KS+-0-CAT
KS+-SV40-CAT
600
500
CREB
CREB+PKA
CREB+PKA*
400
1
PKA
PKA
-
1
300
T
200
100
CAMP
CREM
CREM+CAMP
PKA
CREM+PKA
activity was observed in both the cortex and the medulla and more specifically in a subpopulation of lipid-filled cells (53). Our results show that LPL mRNA and protein is present in the human adrenocortical carcinoma cell line, NCI-H295, and hence suggest that in man LPL is actually produced in the steroid-producing cells of the adrenal cortex.
In the human adrenocortical carcinoma cell line, NCI-H295, LPL expression is regulated by the activation of intracellular second messenger systems, which mediate the effects of specific tropic peptide hormones on adrenal steroidogenesis. PMA-in- duced activation of the PKC pathway, which negatively regu- lates steroidogenesis in adrenal cells (54), results in a time- and dose-dependent decrease in LPL mRNA levels which is accom- panied by decreased secretion of LPL mass and activity in the cell culture medium. In contrast, mobilization of intracellular calcium ion, after treatment with the calcium ionophore A-23187, does not substantially alter LPL gene expression in these cells. This regulation of LPL expression in adrenal cells is comparable to the regulation of the first enzyme in adrenal steroidogenesis, P450scc, whose mRNA levels decrease after PMA, but remain unchanged after A-23187 (24). In contrast, in the human monocytic cell line THP-1 treatment with phorbol esters, which induces a more differentiated macrophage-like phenotype, is accompanied by the induction of LPL expression at the transcriptional level (26, 41). In addition, treatment of THP-1 cells with the calcium ionophore A-23187, induced LPL mRNA levels, possibly also via activation of PKC (41). In con- trast, in the mouse hepatoma cell line, BWTG3, LPL expression appears to be refractory to regulation by stimulators of PKC (27). Therefore, LPL expression appears to be differentially regulated by activators of PKC in different tissues and cell lines.
Addition of cAMP to the culture medium results in a rapid induction of LPL mRNA in NCI-H295 cells. This induction of LPL expression in adrenal cells shows some similarity to the situation in rat mesenchymal heart cells as well as in the neonatal mouse hepatoma cell line BWTG3, where LPL activity
2 B. Staels and J. Auwerx, unpublished observations.
and mRNA levels are induced by activation of the cAMP signal transduction pathway (27, 55). In contrast, elevation of intra- cellular cAMP concentrations decreases LPL synthesis in rat and avian adipocytes (56, 57), but this decrease appears to occur at the (post)translational level (58). In the adrenal cortex, ACTH activates steroidogenesis resulting in an increased pro- duction of glucocorticoid hormones by the zona fasciculata and reticularis. By increasing adenylate cyclase activity, ACTH increases intracellular cAMP concentrations resulting in the activation of PKA. In contrast to the induction by cAMP of most steroidogenic enzymes, such as P450scc, P450c17, and P450c21 (24), this induction is only transient and LPL mRNA levels return within 12-24 h after treatment to pretreatment baseline levels. Remarkably, addition of the protein synthesis inhibitor, CHX, induces LPL mRNA levels. In contrast to P450scc, whose induction is independent of ongoing protein synthesis (this study and Ref. 24), simultaneous addition of cAMP and CHX results in a marked superinduction of LPL gene expression. These results indicate that LPL expression is under control of a labile negative regulatory protein, which represses LPL ex- pression. A similar situation is also observed in THP-1 cells, where CHX treatment induces LPL mRNA levels and simulta- neous addition of PMA and CHX results in a superinduction of LPL mRNA, albeit less pronounced compared to NCI-H295 cells (41). The results from the nuclear run-on experiments with NCI-H295 cells indicate that CHX treatment does not induce LPL gene transcription, thereby indicating that this labile negative regulatory protein regulates LPL expression at a post-transcriptional level, most likely by affecting LPL RNA stability.
The nuclear run-on experiments indicate that cAMP rapidly (within 2 h) activates LPL (and P450scc) expression at the transcriptional level. Furthermore, transient transfection as- says in NCI-H295 cells suggest that the cAMP-mediated acti- vation of LPL transcription is mediated by a cis-acting ele- ment(s) located within the first 230 bp of the proximal human LPL promoter region. Co-transfection of wild-type, but not mutated, PKA expression vector by itself is sufficient to induce LPL gene transcription in NCI-H295 cells. Although the exact nature of the cAMP-response element and the transcription factors implicated in its activation remain to be determined, our co-transfection experiments suggest a functional implica- tion of the cAMP-response element-binding proteins of the CREM/CREB family. In addition, transient transfection exper- iments performed in placenta-derived choriocarcinoma JEG-3 cells, another human steroidogenic cell line, indicate that these elements are functional and can be activated by PKA and CREB in steroidogenic cells derived from other tissues. Al- though JEG-3 cells do not express the endogenous LPL gene,2 the P450scc gene is expressed and activated by cAMP in these cells (47).
Although the transcriptional induction of steroidogenic en- zymes after cAMP treatment appears to be mediated by cAMP- dependent protein kinases (2, 54, 59), the involvement of tran- scription factors belonging to the CREB/CREM family is presently unclear. Purified CREB protein has been demon- strated to bind to a near-classical CRE in the P450c11ß and P450scc genes, but functional transactivation experiments have not yet been performed (60-62). Furthermore, CREB or related factors have been shown to regulate the P450c17 and P450c21 genes (63, 64). Since the transcription activation of steroidogenic enzymes has been shown to be relatively slow (several hours) in adult bovine adrenal cells (3), it has been suggested, however, that the CRE/CREB system might not be involved in the response to cAMP (65). In contrast to bovine adrenal cells, the induction of both LPL and P450scc gene
transcription by cAMP in human NCI-H295 cells is rapid (with- in 2 h). Whether these differences are due to differences be- tween species (human versus bovine) or cell model systems (primary adrenal cells versus adrenocortical carcinoma cells) is presently unclear, but the observations from this study suggest that the CRE/CREB system may be functionally involved in mediating the cAMP response of the LPL gene in human ad- renal NCI-H295 cells. It is most likely that adrenal cortex basal and cAMP-activated gene expression requires cooperation be- tween the classical CRE-binding proteins, CREB/CREM, dif- ferent specific adrenal-enriched transcription factors, and ubiq- uitous transcription factors, such as Sp1, binding to cAMP- responsive elements and to adjacent sites (65). Specific adrenal-enriched transcription factors, such as NGFI-B/nur77, SF-1/Ad4BP, and DAX-1 (66-69), may enhance the cAMP re- sponsiveness of various genes involved in steroidogenesis (62, 70-73). Whether these adrenal-enriched transcription factors participate in the basal and cAMP-mediated expression of the LPL gene awaits further studies.
This coordinate regulation of the LPL gene and the first enzyme of adrenal steroidogenesis, P450scc, suggests a func- tional role of LPL in adrenal steroidogenesis. Although the exact function of LPL in the adrenal gland cannot be deduced from this study, it is tempting to speculate about its potential role. Through its enzymatic activity, hydrolyzing triglycerides and releasing free fatty acids which can be taken up by the underlying tissue, LPL may help the cell to provide in its energy requirements. In this respect, it is interesting to note that LPL expression has been detected in (parts of) tissues displaying a high metabolic activity, such as muscle (74, 75). Alternatively, LPL may be involved in the uptake of lipoprotein cholesterol required for steroidogenesis by the adrenal gland, as has been suggested for rat adrenal cells (76). By locally increasing hydrolysis of VLDL triglycerides LPL may change the conformation of lipoprotein particles rendering them more accessible for binding to the receptors of the underlying tissue. Although the LDL receptor plays a major role in cholesterol delivery to the adrenal gland (6-8), the absence of adrenal dysfunction in patients with defects in the LDL receptor path- way upon treatment with hydroxy 3-methylglutaryl-CoA re- ductase inhibitors, has implicated the existence of alternative routes for cholesterol delivery to the adrenal (10). Separate from its enzymatic function, LPL has been shown to mediate binding of cholesterol-rich remnant lipoprotein particles to spe- cific cell surface receptors, such as the LDL receptor-related protein, thereby mediating their uptake. In this respect, it is interesting to note that NCI-H295 cells express high levels of LDL receptor-related protein,3 which may, in part, explain the localization of LPL protein on the outer cell membrane. Finally, the fact that LPL expression is not confined to the adrenal, but is also observed in other steroidogenic tissues, such as the ovary, points to the requirement of this enzyme in other ste- roidogenic tissues (13).
In conclusion, these results demonstrate the presence of LPL mRNA in fetal and adult adrenal cortex and in the steroid- synthesizing adrenocortical carcinoma cells NCI-H295. In NCI- H295 cells LPL expression is regulated by cAMP and phorbol esters, activators of the PKA and PKC second messenger path- ways, respectively, in a manner reminiscent of the regulation of the first enzyme in adrenal steroidogenesis, P450scc. These data therefore suggest a role for LPL in adrenal energy and lipoprotein metabolism.
Acknowledgments-We are grateful to Delphine Cayet, David García, Susanna Castel, and Jaume Comas for their expert technical
3 B. Staels, F. van Leuven, and J. Auwerx, unpublished observations.
LPL Regulation in Human Adrenal Cortex
assistance and to Dr. K. Schoonjans for helpful suggestions on the transfections. Drs. S. Deeb, P. Sassone-Corsi, and S. McKnight are kindly thanked for providing the various expression vectors.
REFERENCES
1. Miller, W. L., and Tyrrell, J. B. (1995) in The Adrenal Cortex (Felig, P., Baxter, J., and Frohman, L., eds) McGraw Hill Inc., New York
2. Waterman, M. R., and Simpson, E. R. (1989) Recent Prog. Horm. Res. 45, 533-566
3. John, M. E., John, M. C., Boggaram, V., Simpson, E. R., and Waterman, M. R. (1986) Proc. Natl. Acad. Sci. U. S. A. 83, 4715-4719
4. John, M. E., John, M. C., Ashley, P., MacDonald, R. J., Simpson, E. R., and Waterman, M. R. (1984) Proc. Natl. Acad. Sci. U. S. A. 81, 5628-5632
5. DiBlasio, A. M., Voutilainen, R., Jaffe, R. B., and Miller, W. L. (1988) J. Clin. Endocrinol. & Metab. 65, 170-175
6. Gwynne, J. T., and Strauss, J. F. (1982) Endocr. Rev. 3, 299-329
7. Kovanen, P. T., Faust, J. R., Brown, M. S., and Goldstein, J. L. (1979) Endo- crinology 104, 599-609
8. Carr, B. R., and Simpson, E. R. (1981) Endocr. Rev. 2, 306-326
9. Illingworth, D. R., Lees, A. M., and Lees, R. S. (1983) Metabolism 30, 1045
10. Laue, L., Hoeg, J. M., Barnes, K., Loriaux, D. L., and Chrousos, G. P. (1987) J. Clin. Endocrinol. & Metab. 64, 531-535
11. Auwerx, J., Leroy, P., and Schoonjans, K. (1992) Crit. Rev. Clin. Lab. Sci. 29, 243-268
12. Takahashi, S., Suzuki, J., Kohno, M., Oida, K., Tamai, T., Miyabo, S., Yamamoto, T., and Nakai, T. (1995) J. Biol. Chem. 270, 15747-15754
13. Beisiegel, U., Weber, W., and Bengtsson-Olivecrona, G. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 8342-8346
14. Mulder, M., Lombardi, P., Jansen, H., van Berkel, T. J. C., Frants, R. R., and Havekes, L. M. (1993) J. Biol. Chem. 268, 9369-9375
15. Williams, K. J., Fless, G. M., Petrie, K. A., Snyder, M. L., Brocia, R. W., and Swenson, T. L. (1992) J. Biol. Chem. 267, 13284-13292
16. Rumsey, S. C., Obunike, J. C., Arad, Y., Deckelbaum, R. J., and Goldberg, I. J. (1992) J. Clin. Invest. 90, 1504-1512
17. Santamarina-Fojo, S., and Dugi, K. A. (1994) Curr. Opin. Lipidol. 5, 117-125 18. Wion, K. L., Kirchgessner, T. G., Lusis, A. J., Schotz, M. C., and Lawn, R. M. (1987) Science 235, 1638-1641
19. Deeb, S., and Peng, R. (1989) Biochemistry 28, 4131-4135
20. Kirchgessner, T. G., Chuat, J. C., Heinzmann, C., Etienne, J., Guilhot, S., Svenson, K., Ameis, D., Pilon, C., D’auriol, L., Andalibi, A., Schotz, M. C., Galimbert, F., and Lusis, A. J. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 9647-9651
21. Sparkes, R. S., Zollman, S., Klisak, I., Kirchgessner, T. G., Komaromy, M. C., Mohandas, T., Schotz, M. C., and Lusis, A. J. (1987) Genomics 1, 138-144
22. Peinado-Onsurbe, J., Staels, B., Deeb, S., Ramirez, I., Llobera, M., and Auw- erx, J. (1992) Biochim. Biophys. Acta 1131, 281-286
23. Staels, B., and Auwerx, J. (1992) Development 115, 1035-1043
24. Staels, B., Hum, D. W., and Miller, W. L. (1993) Mol. Endocrinol. 7, 423-433
25. Gazdar, A. F., Oie, H. K., Shackleton, C. H., Chen, T. R., Triche, T. J., Myers, C. E., Chrousos, G. P., Brennan, M. F., Stein, C. A., and La-Rocca, R. V. (1990) Cancer Res. 50, 5488-5496
26. Auwerx, J., Deeb, S., Brunzell, J. D., Peng, R., and Chait, A. (1988) Biochem- istry 27, 2651-2655
27. Peinado-Onsurbe, J., Staels, B., Deeb, S., and Auwerx, J. (1992) Biochemistry 31, 10121-10128
28. Guillon, G., Trueba, M., Joubert, D., Grazzini, E., Chouinard, L., Côté, M., Payet, M. D., Manzoni, O., Barberis, C., Robert, M., and Gallo-Payet, N. (1995) Endocrinology 136, 1285-1295
29. Chirgwin, J. M., Przybyla, A. E., MacDonald, R. J., and Rutter, W. J. (1979) Biochemistry 18, 5294-5299
30. Chomczynski, P., and Sacchi, N. (1987) Anal. Biochem. 162, 156-159
31. Tokunaga, K., Nakaruma, Y., Sakata, K., Fujimoro, K., Ohkubo, M., Sawada, K., and Sakiyama, S. (1987) Cancer Res. 47, 5616-5619
32. Chung, B., Matteson, K. J., Voutilainen, R., Mohandas, T. K., and Miller, W. L. (1986) Proc. Natl. Acad. Sci. U. S. A. 83, 8962-8966
33. Nevins, J. R. (1987) Methods Enzymol. 152, 234-241
34. Schoonjans, K., Staels, B., De Vos, P., Szpirer, J., Szpirer, C., Deeb, S., Verhoeven, G., and Auwerx, J. (1993) FEBS Lett. 329, 89-95
35. Gorman, C. M., Moffat, L. F., and Howard, B. H. (1982) Mol. Cell. Biol. 2, 1044-1051
36. de Wet, J. R., Wood, K., DeLuca, M., Helinski, D. R., and Subramani, S. (1987) Mol. Cell. Biol. 7, 725-737
37. Vilella, E., Joven, J., Fernandez, M., Vilaro, S., Brunzell, J. D., Olivecrona, T., and Bengtsson-Olivecrona, G. (1993) J. Lipid Res. 34, 1555-1564
38. Ramirez, I., Kryski, A. J., Ben-Zeev, O., Schotz, M. C., and Severson, D. L. (1985) Biochem. J. 232, 229-236
39. Burgaya, F., Peinado, J., Vilaro, S., Llobera, M., and Ramirez, M. (1989) Biochem. J. 259, 159-166
40. Busca, R., Pujana, M. A., Pognonec, P., Auwerx, J., Deeb, S. S., Reina, M., and Vilaro, S. (1995) J. Lipid Res. 36, 939-951
41. Auwerx, J., Deeb, S., Brunzell, J. D., Wolfbauer, G., and Chait, A. (1989) Biochemistry 28, 4563-4567
42. Habener, J. F. (1990) Mol. Endocrinol. 4, 1087-1094
43. Lalli, E., and Sassone-Corsi, P. (1994) J. Biol. Chem. 269, 17359-17362
44. Gonzalez, G. A., and Montminy, M. R. (1989) Cell 59, 675-680
45. de Groot, R. P., den Hertog, J., Vandenheede, J. R., Goris, J., and Sassone- Corsi, P. (1993) EMBO J. 12, 3903-3911
46. Foulkes, N. S., Mellström, B., Benusiglio, E., and Sassone-Corsi, P. (1992) Nature 355, 80-84
47. Moore, C. C. D., Hum, D. W., and Miller, W. L. (1992) Mol. Endocrinol. 6, 2045-2058
48. Ringler, G. E., Kao, L., Miller, W. L., and Strauss, J. F. I. (1989) Mol. Cell. Endocrinol. 62, 13-21
49. Gotoda, T., Senda, M., Gamou, T., Furuichi, Y., and Oka, K. (1989) Nucleic Acids Res. 17, 2351
50. Semenkovich, C. F., Chen, S .- H., Wims, M., Luo, C .- C., Li, W .- H., and Chan, L. (1989) J. Lipid Res. 30, 423-431
51. Kirchgessner, T. G., Svenson, K. L., Lusis, A. J., and Schotz, M. C. (1987) J. Biol. Chem. 262, 8463-8466
52. Goldberg, I. J., Soprano, D. R., Wyatt, M. L., Vanni, T. M., Kirchgessner, T. G., and Schotz, M. C. (1989) J. Lipid Res. 30, 1569-1577
53. Gafvels, M., Vilaro, S., and Olivecrona, T. (1991) J. Endocrinol. 129, 213-220 54. Reyland, M. E. (1993) Mol. Endocrinol. 7, 1021-1030
55. Friedman, G., Reshef, A., Ben-Naim, M., Leitersdorf, E., Stein, O., and Stein, Y. (1992) Biochim. Biophys. Acta 1137, 237-241
56. Knobler, H., Chajek-Shaul, T., Stein, O., Etienne, J., and Stein, Y. (1984) Biochim. Biophys. Acta 795, 363-371
57. Bensadoun, A., and Marita, R. A. (1986) Biochim. Biophys. Acta 879, 253-263 58. Ong, J. M., Saffari, B., Simsolo, R. B., and Kern, P. A. (1992) Mol. Endocrinol. 6,61-69
59. Wong, M., Rice, D. A., Parker, K. L., and Schimmer, B. P. (1989) J. Biol. Chem. 264, 12867-12871
60. Honda, S .- I., Morohashi, K .- I., and Omura, T. (1990) J. Biochem. (Tokyo) 108, 1042-1049
61. Hashimoto, T., Morohashi, K .- I., Takayama, K., Honda, S .- I., Wada, T., Handa, H., and Omura, T. (1992) J. Biochem. (Tokyo) 12, 573-575
62. Watanabe, N., Inoue, H., and Fujii-Kuriyama, Y. (1994) Eur. J. Biochem. 222, 825-834
63. Watanabe, N., Kitazume, M., Fijisawa, J., Yoshida, M., and Fujii-Kuriyama, Y. (1993) Eur. J. Biochem. 214, 521-531
64. Lund, J., Ahlgren, R., Wu, D., Kagimoto, M., Simpson, E. R., and Waterman, M. R. (1990) J. Biol. Chem. 265, 3304-3312
65. Waterman, M. R. (1994) J. Biol. Chem. 269, 27783-27786
66. Lala, D. S., Rice, D. A., and Parker, K. L. (1992) Mol. Endocrinol. 6, 1249-1258
67. Honda, S .- I., Morohashi, K., Nomura, M., Takeya, H., Kitajima, M., and Omura, T. (1993) J. Biol. Chem. 268, 7494-7502
68. Zanaria, E., Muscatelli, F., Bardoni, B., Strom, T. M., Guioli, S., Guo, W., Lalli, E., Moser, C., Walker, A. P., McCabe, E. R. B., Meitinger, T., Monaco, A. P., Sassone-Corsi, P., and Camerino, G. (1994) Nature 372, 635-641
69. Muscatelli, F., Strom, T. M., Walker, A. P., Zanaria, E., Récan, D., Meindi, A., Bardoni, B., Guioli, S., Zehetner, G., Rabl, W., Schwarz, H. P., Kaplan, J .- C., Camerino, G., Meitinger, T., and Monaco, A. P. (1994) Nature 372, 672-676
70. Morohashi, K .- I., Zanger, U. M., Honda, S .- I., Hara, M., Waterman, M. R., and Omura, T. (1993) Mol. Endocrinol. 7, 1196-1204
71. Clemens, J. W., Lala, D. S., Parker, K. L., and Richards, J. S. (1994) Endocri- nology 134, 1499-1508
72. Wilson, T. E., Mouw, A. R., Weaver, C. A., Milbrandt, J., and Parker, K. L. (1993) Mol. Cell. Biol. 13, 861-868
73. Zhang, P., and Mellon, S. H. (1996) Mol. Endocrinol. 10, 147-158
74. Eckel, R. H., and Robbins, R. J. (1984) Proc. Natl. Acad. Sci. U. S. A. 81, 7604-7607
75. Chajek, T., Stein, O., and Stein, Y. (1977) J. Lipid Res. 26, 549-561
76. Leitersdorf, E., Israeli, A., Stein, O., Eisenberg, S., and Stein, Y. (1986) Bio- chim. Biophys. Acta 878, 320-329
jbc The Journal of Biological Chemistry
AFFINITY SITES
ASBMB American Society for Biochemistry and Molecular Biology
Nucleic Acids, Protein Synthesis, and Molecular Genetics: Expression and Regulation of the Lipoprotein Lipase Gene in Human Adrenal Cortex
Bart Staels, Geneviève Martin, Monica Martinez, Caroline Albert, Julia Peinado-Onsurbe, Régis Saladin, Dean W. Hum, Manuel Reina, Senen Vilaro and Johan Auwerx J. Biol. Chem. 1996, 271:17425-17432. doi: 10.1074/jbc.271.29.17425
Access the most updated version of this article at http://www.jbc.org/content/271/29/17425
Find articles, minireviews, Reflections and Classics on similar topics on the JBC Affinity Sites.
Alerts:
· When this article is cited
· When a correction for this article is posted
Click here to choose from all of JBC’s e-mail alerts
This article cites 75 references, 30 of which can be accessed free at http://www.jbc.org/content/271/29/17425.full.html#ref-list-1